We are live on ! Find out more
REPL icon

Replimune Group

141 hedge funds and large institutions have $1.27B invested in Replimune Group in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 59 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $949M → $1.27B (+$318M)

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

1% more funds holding

Funds holding: 140141 (+1)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

0.48% less ownership

Funds ownership: 94.98%94.5% (-0.48%)

24% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 59

34% less call options, than puts

Call options by funds: $9.34M | Put options by funds: $14.2M

Holders
141
Holders Change
+1
Holders Change %
+0.71%
% of All Funds
2.21%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
20
Increased
45
Reduced
59
Closed
19
Calls
$9.34M
Puts
$14.2M
Net Calls
-$4.83M
Net Calls Change
-$4.98M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$133M +$4.64M +237,396 +4%
BBA
2
Baker Bros. Advisors
New York
$106M
RG
3
Redmile Group
California
$103M +$11.9M +608,545 +16%
BlackRock
4
BlackRock
New York
$81.1M -$2.5M -128,058 -4%
OFM
5
Omega Fund Management
Massachusetts
$69.7M -$955K -48,868 -2%
Vanguard Group
6
Vanguard Group
Pennsylvania
$54.7M -$557K -28,492 -1%
BI
7
BVF Inc
California
$49.8M
AVLSA
8
Atlas Venture Life Science Advisors
Massachusetts
$48.7M
State Street
9
State Street
Massachusetts
$48.5M -$15.9M -815,373 -28%
CCM
10
Camber Capital Management
Massachusetts
$36M +$5.86M +300,000 +24%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$35.9M +$7.64M +391,114 +34%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$29.8M +$4.06M +207,966 +19%
Marshall Wace
13
Marshall Wace
United Kingdom
$28.6M +$11.5M +586,336 +91%
Loomis, Sayles & Company
14
Loomis, Sayles & Company
Massachusetts
$27.6M +$4.47M +228,561 +24%
Citadel Advisors
15
Citadel Advisors
Florida
$26.4M +$414K +21,206 +2%
EA
16
Emerald Advisers
Pennsylvania
$25.2M +$2.41M +123,246 +13%
Lord, Abbett & Co
17
Lord, Abbett & Co
New Jersey
$24.1M +$20.3M +1,038,506 New
EMFAT
18
Emerald Mutual Fund Advisers Trust
Pennsylvania
$20.9M +$1.91M +97,504 +12%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$18.6M -$516K -26,416 -3%
T. Rowe Price Investment Management
20
T. Rowe Price Investment Management
Maryland
$16.9M -$9.82M -502,531 -41%
Morgan Stanley
21
Morgan Stanley
New York
$15.2M -$3.83M -195,884 -23%
Goldman Sachs
22
Goldman Sachs
New York
$14.2M -$614K -31,424 -5%
CS
23
Candriam SCA
Luxembourg
$14.2M -$991K -50,729 -8%
AG
24
Artal Group
Luxembourg
$11.6M
B
25
Braidwell
Connecticut
$11.3M +$8.09M +413,855 +562%

REPL Hedge Fund Activity: Q2 2023 in Review

141 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q2 2023, worth a combined $1.27B — up 34% from $949M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new REPL positions and 19 closed out — a net gain of 1 holder — while 45 added to existing stakes and 59 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $20.3M. The largest seller was State Street, cutting an estimated $15.9M.

  • 141 institutional investors held Replimune Group (REPL) as of Q2 2023, up from 140 in Q1 2023.
  • Funds reported $1.27B of Replimune Group stock for Q2 2023, up 34% quarter-over-quarter.
  • 20 funds opened new Replimune Group positions in Q2 2023 and 19 closed out, a net change of +1 holder.
  • The largest Replimune Group buyer in Q2 2023 was Lord, Abbett & Co, an estimated $20.3M added.
  • The largest Replimune Group seller in Q2 2023 was State Street, an estimated $15.9M sold.

Based on aggregated 13F filings for Q2 2023.